/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2024-04-04 08:00:252024-04-04 08:03:08iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2024-03-05 19:31:452024-03-05 19:33:00iECURE Secures Approval from U.K. Medicines & Healthcare Products Regulatory Agency to Expand the OTC-HOPE Study of ECUR-506
/wp-content/uploads/iEcure_logo.png00eallison/wp-content/uploads/iEcure_logo.pngeallison2023-12-12 18:17:352023-12-13 08:07:51iECURE Secures Clearance from Australian Therapeutic Goods Administration for its Clinical Trial Approval for the OTC-HOPE Phase 1/2 Study of ECUR-506
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2023-03-21 18:54:482023-03-24 17:25:20European Commission Grants Orphan Designation for iECURE’s Lead Product Candidate GTP-506 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2023-03-15 19:15:252023-03-23 14:57:07iECURE Appoints Gabriel M. Cohn, M.D., as Chief Medical Officer
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2022-11-30 00:00:412023-03-24 17:26:58iECURE Raises $65 Million to Advance In Vivo Gene Editing Programs for the Treatment of Rare Pediatric Liver Diseases
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2022-10-19 08:00:312023-03-24 17:28:32Preclinical Data from iECURE’s GTP-506 Demonstrates Potential for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2022-09-02 20:04:532023-03-24 17:30:23iECURE Receives FDA Orphan Drug Designation for GTP-506, an Investigational Gene Editing Product Candidate for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
/wp-content/uploads/iEcure_logo.png00eallison/wp-content/uploads/iEcure_logo.pngeallison2022-08-22 19:18:032023-03-24 17:37:04iECURE Receives FDA Rare Pediatric Disease Designation for GTP-506, an Investigational Gene Editing Product Candidate for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2022-05-25 05:00:362022-05-25 08:00:43iECURE Enters Agreement with Center for Breakthrough Medicines (CBM) to Supply Materials for Future Clinical Programs
